BCL2L1 and neoplasm: Together with STAT5, they activate transcription of Bcl-x, producing the anti-apoptotic protein Bcl-xL. As the Bcl-xL production goes up, it facilitates the tumour cells to adapt to a hypoxic environment, promotes angiogenesis and suppresses anti-tumour immune responses (Thomas et al., 2015).